Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients

Supplementary Material
Supplemental Table 1 : Clinicopathological characteristics of screening set consisting of 10 long-term and 14 short-term surviving GBM patients. All sera were obtained preoperatively from therapy-naïve patients. Board-certified neuropathologists verified diagnosis of all tumor specimens. The majority of patients received adjuvant radiochemotherapy. *p<0.05, **p<0.01, ***p<0.001. Figure 1 : Representative scans of screening PEPperCHIP® microarray (1745 peptides) for a long-term (LTS) and a short-term surviving (STS) patient. A red fluorescent labeled secondary antibody binding to the human heavy chain visualized patient antibodies specifically bound to spotted peptides on the array. The red spots on the border of the array denote control spots. Duplicate spots within this border depict antibodies against the candidate antigens.
Supplemental Figure 2 :
Median intensity for all peptides of an antigen on the 1745 PEPperCHIP® screening array. Every scatter plot illustrates the median centered, quantile normalized signal intensity for all peptides of an antigen per patient. Differences between STS and LTS patients are shown. P-values were calculated employing Student's t-test. *p<0.05, **p<0.01, ***p<0.001.
Supplemental Figure 3 :
Correlation heatmap between MAGEA3 peptides on the PEPperCHIP® screening array. The signal of each MAGEA3 peptide across all patients is correlated with all other 74 MAGEA3 peptides on the screening array, clustered (hierarchical clustering) and illustrated in a heatmap. Blue color denotes a high correlation.
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